BBNX Company Profile and Key Details

NASDAQ : BBNX

Beta Bionics

$20.14

-11.85-37.04%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Beta Bionics, Inc. (BBNX) stock declined over -37.04%, trading at $20.14 on NASDAQ, down from the previous close of $31.99. The stock opened at $22.75, fluctuating between $20.03 and $23.92 in the recent session.

Stock Snapshot

31.99

Prev. Close

886.57M

Market Cap

20.03

Day Low

-10.38

P/E Ratio

-1.94

EPS (TTM)

N/A

Cash Flow per Share

22.75

Open

44.02M

Number of Shares

23.92

Day High

75.35%

Free Float in %

N/A

Book Value

8.29M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	22.75	23.92	20.02	20.14	7.77M
Jan 08, 2026	30.43	32.58	30.43	31.99	655.61K
Jan 07, 2026	31.40	32.53	31.20	31.49	639.56K
Jan 06, 2026	29.44	31.42	29.13	31.40	430.18K
Jan 05, 2026	29.25	29.89	28.36	29.57	473.62K
Jan 02, 2026	30.70	31.09	28.91	29.25	781.51K
Dec 31, 2025	31.97	32.21	30.44	30.47	924.65K
Dec 30, 2025	31.37	32.03	30.86	31.97	526.74K
Dec 29, 2025	31.53	31.57	30.80	31.27	349.4K
Dec 26, 2025	31.08	31.87	30.32	31.86	374.22K
Dec 24, 2025	31.35	31.78	30.81	31.09	643.55K
Dec 23, 2025	31.20	32.05	30.44	31.35	588.36K
Dec 22, 2025	29.17	32.26	28.59	31.69	2.36M
Dec 19, 2025	28.97	30.07	28.65	29.25	1.51M
Dec 17, 2025	29.63	30.06	29.06	29.19	1.55M
Dec 16, 2025	29.41	29.78	27.86	29.63	668.24K
Dec 15, 2025	29.79	30.05	28.85	29.72	1.2M
Dec 12, 2025	29.46	30.50	28.84	29.76	776.12K
Dec 11, 2025	29.18	29.67	28.76	29.31	617.26K
Dec 10, 2025	29.09	29.67	28.01	29.19	888.68K

Contact Details

Irvine, CA 92618

United States

https://www.betabionics.com 949 427 7785

About Company

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Stock Peers

PARK

0.22+1.54%

Park Dental Partners, Inc. Common Stock$14.53 KDLY

0.13+1.16%

Kindly MD, Inc.$11.30 CV

-0.9-12.86%

CapsoVision, Inc.$6.10 NAKA

-0.018-4.04%

Kindly MD, Inc.$0.43 PFSA

-0.0038-3.88%

Profusa, Inc. Common Stock$0.09

Company Overview

Beta Bionics, Inc. (NASDAQ:BBNX) closed at $20.14 USD, losing -$11.85 (-37.04%) from the previous close of $31.99. The stock is currently mid-range between its 52-week high and low $8.89 and $32.71. With a market capitalization of about $886.57 million, Beta Bionics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~5.74). Key stats such as the average daily volume over the past year has been around 904.05 thousand shares, trading with heavier-than-usual volume. Headquartered in Irvine, CA, Beta Bionics, Inc. operates in the Healthcare sector and the Medical - Equipment & Services industry. Led by CEO Sean T. Saint, the company employs approximately 352 people and listed since January 30, 2025. Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

Technical Performance

BBNX has shown sold momentum, gaining 4.99% over the past week and 44.42% over the past quarter, though year-to-date performance is up 4.99%. Short-term trend indicators are bearishly aligned (SMA20 -32.81%, SMA50 -30.68%, SMA200 2.36%). The stock’s 14-day RSI is 26.79 (weak momentum), while the ATR of 2.51 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -38.43% below its high and over 126.55% above its low. Average 10-day trading volume of 1.79 million shares is significantly above the 3-month average of 856.85 thousand, indicating heightened recent market interest.

Valuation Metrics

Beta Bionics, Inc. trades at a P/E ratio of -11.29, slightly below the S&P 500 average, with a price-to-sales ratio of 10.01 and a price-to-book ratio of 2.98 suggesting the stock is closer to book value. The P/FCF stands at -14.65, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 41.39% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 14 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $16.00. The high target offers 98.61% upside. The low target suggests -20.56% downside. The mean target is $27.90. This offers 38.53% upside. Beta Bionics, Inc. earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -26.67%. The prior quarter beat by -23.53%. Over the last six quarters, Apple has recorded several small beats. These include 333.33% in March 25, 2025.

Shareholding & Insider Activity

Beta Bionics, Inc. has 43.47 million shares outstanding. The public float is 23.70 million shares, elevated short interest at 16.58% of float. This equals 6.38 million shares. The short ratio is 5.77 days. Institutional investors hold 123.38% of the float. Insiders own 10.42%. Saint Sean holds 97.92 thousand shares, Mensinger Mike has 80.75 thousand shares and Russell Steven Jon has 71.02 thousand shares. Over the past six months, insider transactions show net selling. They sold 93.14 thousand shares across 24 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Beta Bionics has not generated any revenue.
On valuation metrics, Beta Bionics trades at a P/E of -11.29, P/S of 10.01 and P/B of 2.98. The current ratio is 10.64 and quick ratio is 9.83. Operationally, the company’s inventory turnover is 1.98 and cash conversion cycle is 202.90 days. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of -7.36.

Price Forecast & Outlook

Our AI price prediction model suggests that Beta Bionics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 27.76%, with price expected at $25.73 by January 23, 2026, within a range of $23.45 to $27.89 3-Month Outlook: Projected rise of 28.95%, reaching $25.97 by April 09, 2026, with a range of $25.58 to $26.45. 1-Year Outlook: Projected gain of 116.24%, with price at $43.55 by December 31, 2026, within a range of $42.22 to $45.03.

Key Takeaways

Beta Bionics, Inc. (NASDAQ:BBNX) shares are flat 4.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Beta Bionics, Inc. trading at a premium to the broader market with a P/E of -11.29. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $27.90, suggesting 38.53% upside. Our AI forecast model points to short-term strength (27.76% over two weeks), a medium-term rise (28.95% over three months), and a longer-term gain (116.24% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Beta Bionics, Inc. (BBNX) stock price?

Beta Bionics, Inc. (NASDAQ: BBNX) stock price is $20.14 in the last trading session. During the trading session, BBNX stock reached the peak price of $23.92 while $20.03 was the lowest point it dropped to. The percentage change in BBNX stock occurred in the recent session was -37.04% while the dollar amount for the price change in BBNX stock was - $11.85.

BBNX's industry and sector of operation?

The NASDAQ listed BBNX is part of Medical - Equipment & Services industry that operates in the broader Healthcare sector. Beta Bionics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BBNX?

No Data

How BBNX did perform over past 52-week?

BBNX's closing price is 126.55% higher than its 52-week low of $8.89 where as its distance from 52-week high of $32.71 is -38.43%.

How many employees does BBNX have?

Number of BBNX employees currently stands at 352.

Link for BBNX official website?

Official Website of BBNX is: https://www.betabionics.com

How do I contact BBNX?

BBNX could be contacted at phone 949 427 7785 and can also be accessed through its website. BBNX operates from 11 Hughes, Irvine, CA 92618, United States.

How many shares of BBNX are traded daily?

BBNX stock volume for the day was 8.29M shares. The average number of BBNX shares traded daily for last 3 months was 904.05K.

What is the market cap of BBNX currently?

The market value of BBNX currently stands at $886.57M with its latest stock price at $20.14 and 44.02M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	352
Beta	5.74
Sales or Revenue	N/A
5Y Sales Change%	62.143%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Medical - Equipment & Services

BBNX Company Profile and Key Details

Beta Bionics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways